Therapeutic Advances in Hematology

Scope & Guideline

Unlocking new horizons in hematological advancements.

Introduction

Welcome to the Therapeutic Advances in Hematology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Therapeutic Advances in Hematology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2040-6207
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2016, from 2018 to 2024
AbbreviationTHER ADV HEMATOL / Ther. Adv. Hematol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Therapeutic Advances in Hematology focuses on advancing the understanding and treatment of hematological disorders through innovative research and clinical studies. The journal emphasizes multidisciplinary approaches and encourages contributions that enhance patient care and treatment outcomes.
  1. Hematological Malignancies:
    Research on various hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, and lymphomas, focusing on novel therapeutic strategies and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Exploration of topics related to transfusion practices, management of bleeding disorders, and advancements in therapies for hemophilia and thrombocytopenia.
  3. Stem Cell Transplantation and Gene Therapy:
    Studies addressing the role of hematopoietic stem cell transplantation (HSCT), including conditioning regimens, donor selection, and the integration of gene therapy in treating hematological diseases.
  4. Patient-Reported Outcomes and Quality of Life:
    Research that evaluates the impact of hematological diseases and their treatments on patients' quality of life, incorporating patient-reported outcomes to inform treatment decisions.
  5. Innovative Treatment Modalities:
    Investigation into new treatment modalities such as CAR-T therapy, bispecific antibodies, and targeted therapies, with a focus on their efficacy and safety in various hematological conditions.
The journal has demonstrated a dynamic evolution in its research themes, with several emerging topics reflecting the latest advancements and priorities in hematology.
  1. Targeted and Personalized Therapies:
    A growing emphasis on targeted therapies, such as B-cell maturation antigen (BCMA) targeting in multiple myeloma, reflects the shift towards personalized medicine tailored to individual genetic profiles.
  2. Immunotherapy Advances:
    The rise of immunotherapeutic strategies, including CAR-T cell therapy and bispecific antibodies, indicates a significant trend towards harnessing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Patient Experience:
    Increased attention to real-world evidence and patient-reported outcomes highlights the importance of understanding treatment impacts from the patient's perspective, influencing clinical practice.
  4. Innovations in Hematopoietic Stem Cell Transplantation:
    Research focusing on advancements in HSCT techniques, including the use of haploidentical donors and novel conditioning regimens, is becoming more prominent as these methods improve patient outcomes.
  5. Management of Rare Hematological Disorders:
    There is an emerging focus on the management and treatment of rare hematological conditions, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria, addressing unmet medical needs.

Declining or Waning

While Therapeutic Advances in Hematology continues to publish impactful research, certain themes appear to be declining in prominence over recent years, potentially reflecting shifts in research focus or advancements in treatment options.
  1. Traditional Chemotherapy Approaches:
    The focus on traditional chemotherapy regimens appears to be waning, as newer targeted therapies and immunotherapies gain prominence in treatment paradigms for hematological malignancies.
  2. Historical Case Reports:
    The journal has seen a decrease in the publication of historical or anecdotal case reports, as the emphasis shifts towards larger, evidence-based studies and clinical trials.
  3. Generalized Treatment Guidelines:
    There is less emphasis on broad treatment guidelines that do not consider individual patient characteristics, as precision medicine and personalized treatment strategies become more prevalent.
  4. Epidemiological Studies:
    Research focused solely on epidemiological data without direct clinical implications seems to be less prioritized, as the journal emphasizes studies that directly impact treatment outcomes and patient care.

Similar Journals

Blood Cancer Journal

Innovating research for a brighter future in blood cancer.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Fostering dialogue in the realm of child health and treatment.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Indian Journal of Hematology and Blood Transfusion

Pioneering Research in Hematology for Tomorrow's Healthcare
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

AMERICAN JOURNAL OF HEMATOLOGY

Connecting Scholars to Shape the Future of Hematology
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Hematologie

Pioneering Discoveries in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Mediterranean Journal of Hematology and Infectious Diseases

Advancing knowledge in hematology and infectious diseases.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

BLOOD

Transforming Insights into Blood Science.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

ACTA HAEMATOLOGICA

Pioneering Insights into Hematological Practices
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

Egyptian Journal of Haematology

Pioneering Knowledge in Hematologic Malignancies and Care
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Journal of Blood Medicine

Pioneering Discoveries: Shaping the Future of Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.